Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Ovarian Cancer

Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation

Bone Marrow Transplantation volume 33, pages 1219–1224 (2004)Cite this article

Summary:

The purpose of this study was to identify characteristics significant to survival and progression-free survival in patients with advanced ovarian cancer receiving high-dose chemotherapy. In all, 96 patients received autologous stem cell transplantation. Regimens included paclitaxel with carboplatin (PC), topotecan, melphalan, cyclophosphamide (TMC) and cyclophosphamide, BCNU, thiotepa (CBT). At the time of transplantation, 43% of patients were in clinical CR, 34% were in clinical PR, 18% had progressive disease and 5% had stable disease. There were no treatment-related deaths. The 6-year survival by Kaplan–Meier was 38%. For patients who received transplantation for remission consolidation, the 6-year survival was 53% with a PFS of 29%. On univariate analysis, the CBT regimen, clear cell histology and disease status other than CR prior to treatment were statistically significant adverse prognostic factors. This analysis has demonstrated that patients in clinical remission are most likely to benefit from autologous transplantation, with the exception of patients with clear cell histology. The TMC combination appeared to be superior to the PC and CBT combinations. Comparative studies of different consolidation approaches will be necessary to determine if autologous transplantation is the preferred treatment for this patient population.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Oriel KA, Hartenbach EM, Remington PL . Trends in United States ovarian cancer mortality, 1979–1995. Obstet Gynecol 1999; 93: 30–33.

    CAS  PubMed  Google Scholar 

  2. Hanai A . Trends and differentials in ovarian cancer: incidence, mortality and survival experience. APMIS 1990; 98 (Suppl. 12): 1–20.

    Google Scholar 

  3. Yancik R . Ovarian cancer: age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 1993; 71 (Suppl. 2): 517–523.

    CAS  PubMed  Google Scholar 

  4. Gore M, Mainwaring P, A'Hern R et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol 1998; 16: 2426–2434.

    Article  CAS  Google Scholar 

  5. Donato ML, Gershenson D, Ippoliti C et al. High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone Marrow Transplant 2000; 25: 1137–1140.

    Article  CAS  Google Scholar 

  6. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748–1756.

    Article  CAS  Google Scholar 

  7. Donato ML, Gershenson DM, Wharton JT et al. High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. Gynecol Oncol 2001; 82: 420–426.

    Article  CAS  Google Scholar 

  8. Rustin GJ, Nelstrop AE, McClean P et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996; 14: 1545–1551.

    Article  CAS  Google Scholar 

  9. Clark TG, Stewart ME, Altman DG, Gabra H, Smyth JF . A prognostic model for ovarian cancer. Br J Cancer 2001; 85: 944–952.

    Article  CAS  Google Scholar 

  10. Sugiyama T, Kamura T, Kigawa J et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000; 88: 2584–2589.

    Article  CAS  Google Scholar 

  11. Tammela J, Geisler JP, Eskew Jr PN, Geisler HE . Clear cell carcinoma of the ovary: poor prognosis compared to serous carcinoma. Eur J Gynaecol Oncol 1998; 19: 438–440.

    CAS  PubMed  Google Scholar 

  12. Eren M, Rakar S, Klanar B, Syrjänen K . Endometriosis-associated ovarian carcinoma (EAOC): an entity district from other ovarian carcinomas as suggested by a nested case–control study. Gynecol Oncol 2001; 83: 100–108.

    Article  Google Scholar 

  13. Stiff PJ, Veum-Stone J, Lazarus HM et al. High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: an Autologous Blood and Marrow Transplant Registry Report. Ann Intern Med 2000; 133: 504–515.

    Article  CAS  Google Scholar 

  14. Barakat RR, Sabbatini P, Bhaskaran D et al. Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J Clin Oncol 2002; 20: 694–698.

    Article  Google Scholar 

  15. Tournigand C, Louvet C, Molitor JL et al. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma. Gynecol Oncol 2001; 83: 198–204.

    Article  CAS  Google Scholar 

  16. MacGibbon A, Bucci J, MacLeod C et al. Whole abdominal radiotherapy following second-look laparotomy for ovarian cancer. Gynecol Oncol 1999; 75: 62–67.

    Article  CAS  Google Scholar 

  17. Pickel H, Lahousen M, Petru E et al. Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer. Gynecol Oncol 1999; 72: 215–219.

    Article  CAS  Google Scholar 

  18. Cmelak AJ, Kapp DS . Long-term survival with whole abdominopelvic irradiation in platinum-refractory persistent or recurrent ovarian cancer. Gynecol Oncol 1997; 65: 453–460.

    Article  CAS  Google Scholar 

  19. Lambert ME, Rustin GJ, Gregory WM, Nelstrop AE . A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. Ann Oncol 1997; 8: 327–333.

    Article  CAS  Google Scholar 

  20. Hakes TB, Chalas E, Hoskins WJ et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 1992; 45: 284–289.

    Article  CAS  Google Scholar 

  21. Berek JS, Markman M, Stonebraker B et al. Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group. Gynecol Oncol 1999; 75: 10–14.

    Article  CAS  Google Scholar 

  22. Hortobagyi GN, Ueno NT, Xia W et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I trial. J Clin Oncol 2001; 19: 3422–3433.

    Article  CAS  Google Scholar 

  23. Ledermann JA . High-dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) in ovarian cancer. Int J Gynecol Cancer 2000; 10 (Suppl. 1): 53–56.

    Article  Google Scholar 

  24. Legros M, Dauplat S, Fleury J et al. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results. J Clin Oncol 1997; 15: 1302–1308.

    Article  CAS  Google Scholar 

  25. Stiff PJ, Bayer R, Kerger C et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 1997; 15: 1309–1317.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Blood and Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

    M L Donato, A Aleman, R E Champlin, R M Saliba, C Ippoliti & J L Gajewski

  2. Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

    J T Wharton, T W Burke, D C Bodurka, M W Bevers, C F Levenback, J K Wolf, R C Bast Jr, R S Freedman, M Brewer & D M Gershenson

Authors
  1. M L Donato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Aleman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R E Champlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R M Saliba
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J T Wharton
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T W Burke
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D C Bodurka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M W Bevers
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C F Levenback
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J K Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. R C Bast Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. R S Freedman
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. C Ippoliti
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. M Brewer
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. J L Gajewski
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. D M Gershenson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M L Donato.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Donato, M., Aleman, A., Champlin, R. et al. Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 33, 1219–1224 (2004). https://doi.org/10.1038/sj.bmt.1704473

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704473

Keywords

This article is cited by

Search

Advanced search

Quick links